Therapeutics
Search By Attributes
Search Results
| Name | Synonyms | FDA Status | Company | Target Type | Therapy Type | Approved For |
|---|---|---|---|---|---|---|
| ABvac 40 | Alzheimer's Disease (Phase 2) | Araclon Biotech | Amyloid-Related | Immunotherapy (active) | ||
| ACI-24 | Pal1-15 acetate salt | Alzheimer's Disease (Phase 1/2), Down's Syndrome (Phase 1) | AC Immune SA | Amyloid-Related | Immunotherapy (active) | |
| AN-1792 | AIP 001 | Alzheimer's Disease (Discontinued) | Janssen, Pfizer | Amyloid-Related | Immunotherapy (active) | None |
| Affitope AD02 | Alzheimer's Disease (Phase 2) | AFFiRiS AG | Amyloid-Related | Immunotherapy (active) | ||
| CAD106 | Alzheimer's Disease (Phase 2/3) | Novartis Pharmaceuticals Corporation | Amyloid-Related | Immunotherapy (active) | None | |
| Lu AF20513 | Alzheimer's Disease (Phase 1) | H. Lundbeck, Otsuka Pharmaceutical Co., Ltd. | Amyloid-Related | Immunotherapy (active) | ||
| UB 311 | Alzheimer's Disease (Phase 2) | United Neuroscience | Amyloid-Related | Immunotherapy (active) | ||
| Vanutide cridificar | ACC-001, PF-05236806 |
Alzheimer's Disease (Discontinued) | Janssen | Amyloid-Related | Immunotherapy (active) | None |